STOCK TITAN

Ensysce Biosciences, Inc. - enscw STOCK NEWS

Welcome to our dedicated news page for Ensysce Biosciences (Ticker: enscw), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ensysce Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ensysce Biosciences's position in the market.

Rhea-AI Summary
Ensysce Biosciences, Inc. announces positive results from the clinical study PF614-102 comparing PF614, a novel TAAP prodrug of oxycodone, to OxyContin. The study demonstrates a clear dose relationship between PF614 and oxycodone, achieving bioequivalence with OxyContin. PF614 offers advantages such as similar oxycodone exposures in fasted and fed states, a longer half-life, and potential as a twice-daily pain treatment. The manuscript published in Clinical and Translational Science highlights the safety and pharmacokinetics profile of PF614, positioning it as a promising analgesic for severe pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary
Ensysce Biosciences, Inc. announces the presentation of their lead product, PF614-MPAR, at the NIH HEAL Initiative Scientific Meeting. The drug has been granted Breakthrough Therapy Designation by the FDA and has received funding from NIDA. The company aims to combat abuse and protect against oral opioid overdose, addressing the current opioid crisis. The presentation of the trial data reflects the successful optimization of the drug product, with potential to become a first-in-class 'Next Generation' opioid with abuse deterrent and oral overdose protection properties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.78%
Tags
conferences
-
Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ: ENSC) made significant progress in 2023, focusing on delivering innovative approaches to severe pain with the unique benefit of overdose protection. The company aims to move its lead analgesic through to commercialization and expand its pipeline of products to treat pain. CEO Dr. Lynn Kirkpatrick expressed gratitude for shareholder support and outlined the corporate and clinical milestones achieved in the past year, with a focus on a transformational year in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
none
Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced the completion of enrollment for the PF614-201 study, a critical step towards Phase 3 evaluation of PF614. The study aims to confirm the onset time for PF614 analgesic effects, with trial results expected in December 2023. The company's Chief Medical Officer highlighted the significance of this milestone, emphasizing the potential of PF614 to provide longer and safer exposure to analgesic levels compared to OxyContin, with lower abuse potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.58%
Tags
clinical trial
-
Rhea-AI Summary
Ensysce Biosciences, Inc. has entered into a securities purchase agreement with investors for an aggregate investment of $1.7 million. The funding will support the clinical development of their lead product and advance their unique technologies. The Notes are convertible into shares of Ensysce common stock at a conversion price of $1.5675 and the Warrants have the right to purchase up to 1,255,697 shares of common stock at an exercise price of $1.5675.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.61%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
conferences
Ensysce Biosciences, Inc.

Nasdaq:ENSCW

ENSCW Rankings

ENSCW Stock Data